» Articles » PMID: 38004527

Design, Synthesis, and Antisickling Investigation of a Thiazolidine Prodrug of TD-7 That Prolongs the Duration of Action of Antisickling Aromatic Aldehyde

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2023 Nov 25
PMID 38004527
Authors
Affiliations
Soon will be listed here.
Abstract

The synthetic allosteric effector of hemoglobin, TD-7 has been investigated as a potential therapeutic agent for the treatment of sickle cell disease. The pharmacologic activity of TD-7 is due to formation of a Schiff-base interaction between its aldehyde group and the two N-terminal αVal1 amines of hemoglobin, effectively inhibiting sickling of red blood cells. However, TD-7 faces a challenge in terms of poor oral bioavailability due to rapid in-vivo oxidative metabolism of its aldehyde functional group. To address this shortcoming, researches have explored the use of a L-cysteine ethyl ester group to cap the aldehyde group to form a thiazolidine aromatic aldehyde prodrug complex, resulting in the improvement of the metabolic stability of this class of compounds. This report details the synthesis of a thiazolidine prodrug of TD-7, referred to as Pro-7, along with a comprehensive investigation of Pro-7 functional and biological properties. In an in-vitro Hb modification and Hb oxygen affinity studies using normal whole blood, as well as erythrocyte sickling inhibition using sickle whole blood, Pro-7 exhibited a gradual onset but progressive increase in all activities. Additionally, in-vivo pharmacokinetic studies conducted with Sprague Dawley rats demonstrated that Pro-7 can undergo hydrolysis to release TD-7. However, the blood concentration of TD-7 did not reach the desired therapeutic level. These findings suggest that the incorporation of the L-cysteine ethyl ester group to TD-7 represents a promising strategy to enhance the metabolic stability of aromatic aldehydes that could lead to the development of a more effective drug for the treatment of sickle cell disease.

References
1.
Piccin A, Murphy C, Eakins E, Rondinelli M, Daves M, Vecchiato C . Insight into the complex pathophysiology of sickle cell anaemia and possible treatment. Eur J Haematol. 2019; 102(4):319-330. DOI: 10.1111/ejh.13212. View

2.
Godfrey V, Chen L, Griffin R, Lebetkin E, Burka L . Distribution and metabolism of (5-hydroxymethyl)furfural in male F344 rats and B6C3F1 mice after oral administration. J Toxicol Environ Health A. 1999; 57(3):199-210. DOI: 10.1080/009841099157764. View

3.
Arya R, Rolan P, Wootton R, Posner J, Bellingham A . Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. Br J Haematol. 1996; 93(4):817-21. DOI: 10.1046/j.1365-2141.1996.d01-1744.x. View

4.
Mvalo T, Topazian H, Kamthunzi P, Chen J, Kambalame I, Mafunga P . Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi. Blood Adv. 2018; 2(Suppl 1):30-32. PMC: 6438283. DOI: 10.1182/bloodadvances.2018GS110347. View

5.
Belcher J, Bryant C, Nguyen J, Bowlin P, Kielbik M, Bischof J . Transgenic sickle mice have vascular inflammation. Blood. 2003; 101(10):3953-9. DOI: 10.1182/blood-2002-10-3313. View